Back

Development of a new advanced platform for personalized treatment of transthyretin amyloid cardiomyopathy

31 August 2026 (13:15 - 14:00)
Organised by: Logo
Congress Presentation Part of: Phenotypic approaches to heart failure treatment Pathophysiology ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Doctor Olalla Iglesias Garcia

CIMA University of Navarre, Pamplona, Navarra (Spain)

6 More presentations in this session

Presentation thumbnail
Tumor-driven cytokines IL-13 and IFN-γ ameliorate pressure overload–induced cardiac dysfunction
Ms L. Awwad (Haifa, IL)
Abstract Slides Video
Presentation thumbnail
Investigating the role of neutrophils in trametinib-induced cardiomyopathy
Doctor S. Morrissey (Chapel Hill, US)
Abstract Slides Video
Presentation thumbnail
Influence of invasive ischemic evaluation on mortality in patients with a new onset heart failure after myocardial infarction
Doctor M. Ferreira (Funchal, PT)
Abstract Slides Video
Presentation thumbnail
Effects of empagliflozin according to background angiotensin receptor-neprilysin inhibitor and mineralocorticoid receptor antagonist use in heart failure with reduced ejection fraction (SUGAR-DM-HF)
Doctor M. Lee (Glasgow, GB)
Abstract Slides Video
Presentation thumbnail
The sugar alcohol sweeteners Erythritol and Xylitol are linked with heart failure
Doctor M. Witkowski (Berlin, DE)

Access the full session

Session thumbnail
Phenotypic approaches to heart failure treatment

The Event

Event poster

ESC Congress 2026

31 August 2026 13:15 CET
You may be interested in
thumbnail
Congress Presentation
Engineering hiPSC-derived tissue models for advanced amyloidosis research and therapy development
31 August 2024
thumbnail
Congress Presentation
Electrocardiographic correlates of disease burden in cardiac transthyretin amyloidosis
29 August 2026
thumbnail
Congress Presentation
Unraveling the cardiotoxic effects of wild-type and variant transthyretin: insights from in vitro models
1 September 2025
thumbnail
Congress Presentation
Pathophysiological impact of one year of tafamidis in patients with transthyretin cardiac amyloidosis
30 August 2026

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources